{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T06:43:39Z","timestamp":1784443419374,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaut.2024.103246","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:00:50Z","timestamp":1716472850000},"page":"103246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy"],"prefix":"10.1016","volume":"147","author":[{"given":"F.C.","family":"Moazedi-Fuerst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Odler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Flick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Talakic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brodmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Jud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Yazdani-Biuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Husic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Salmhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Stradner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.B.","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.P.","family":"Brezinschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103246_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.2482","article-title":"The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach","volume":"217","author":"Corriveau","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.jaut.2024.103246_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"Katsumoto","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jaut.2024.103246_bib3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10067-011-1744-z","article-title":"Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients","volume":"30","author":"Foocharoen","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103246_bib4","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol, Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2024.103246_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103246_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology. (Oxford.) Engl.)."},{"key":"10.1016\/j.jaut.2024.103246_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ced.12450","article-title":"Dosage of rituximab in systemic sclerosis: 2-year results of five cases","volume":"40","author":"Moazedi-Fuerst","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.jaut.2024.103246_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"EUSTAR Coauthors, EUSTAR Coauthors, Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib10","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","author":"Maher","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jaut.2024.103246_bib11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/1346-8138.15079","article-title":"Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti\u2010-topoisomerase I\u2010positive systemic sclerosis\u2010associated interstitial lung disease","volume":"46","author":"Ebata","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2024.103246_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"EVER-ILD investigators and the OrphaLung network, Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2024.103246_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.jaut.2024.103246_bib15","first-page":"1","article-title":"B-cell depletion in SLE: Cclinical and trial experience with rituximab and ocrelizumab and implications for study design","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103246_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.15079","article-title":"Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti\u2010-topoisomerase I\u2010positive systemic sclerosis\u2010associated interstitial lung disease","volume":"46","author":"Ebata","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2024.103246_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/1346-8138.16206","article-title":"Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease","volume":"49","author":"Ebata","year":"2022","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2024.103246_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi-Fuerst","year":"2014","journal-title":"Scand. J. Rheumatol."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2024.103246_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2015.1069888","article-title":"Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?","volume":"44","author":"Moazedi-Fuerst","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103246_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ced.12450","article-title":"Dosage of rituximab in systemic sclerosis: 2-year results of five cases","volume":"40","author":"Moazedi-Fuerst","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.jaut.2024.103246_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14069","article-title":"Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: Llong-term experience of a single centre","volume":"75","author":"Odler","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jaut.2024.103246_bib22","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103246_bib23","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League aAgainst Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103246_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.jaut.2024.103246_bib25","first-page":"11","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis, J. Scleroderma Relat","volume":"2","author":"Khanna","year":"2017","journal-title":"Disord"},{"key":"10.1016\/j.jaut.2024.103246_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib27","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in Adults: Aan Official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2024.103246_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.62.9.904","article-title":"European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV., European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score","volume":"62","author":"Valentini","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2021","article-title":"Pulmonary hypertension phenotypes in patients with systemic sclerosis","volume":"30","author":"Haque","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2024.103246_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Sscleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib33","unstructured":"Steierm\u00e4rkische Krankenanstaltengesellschaft m.b.H..H., Vorstandsbereich Medizin und Pflege\/Organisationseinheit Qualit\u00e4tsmanagement, 8010 Graz Stiftingtalstra\u00dfe 4-6, RCQM- Qualit\u00e4tsmanagement Rheumatologie, (n.d.). \u00fc\u00e4\u00dfhttps:\/\/www.kages.at\/cms\/dokumente\/10170471_5058571\/8f5fe720\/Bericht\u00fcberqualit\u00e4tsverbesserndeMa\u00dfnahmenderKAGes2008.pdf (accessed February 24, 2020) 2008.pdf.."},{"key":"10.1016\/j.jaut.2024.103246_bib34","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoOS OneNE"},{"key":"10.1016\/j.jaut.2024.103246_bib35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial Llung Ddisease in Ssystemic Ssclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2024.103246_bib36","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol, Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2024.103246_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rrituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103246_bib38","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR Standards, Guidelines and Audit working group, BSR and BHPR Standards, Guidelines and Audit working group, BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103246_bib40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103246_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/ar2977","article-title":"B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis","volume":"12","author":"van Laar","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103246_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: Aan open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103246_bib42","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T20:30:41Z","timestamp":1720816241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"alternative-id":["S0896841124000805"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103246","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103246"}}